In contemporary oncology, we see the lack of appropriate patient stratification, resulting in drugs often being administered to patients without producing any benefit. This single problem has important consequences such as:
- up to 90% failure rates in clinical trials
- clinical development cost of about 1 bilion dollars per newly approved drug
- growing cost for patient treatment, typically in the range of 10-100 thousand dollars
- reimbursement issues, with up to 75% drugs not accessible in some countries because of their cost
- poor clinical response, with up to 90% failure rates for some cancer types
Such issues still remain despite the development of genetic biomarkers and molecular profiling of the patient.
The efficacy of a drug therapy is the consequence of how drug affects whole cell and tissue biology. However, current practices in precision medicine are limited to DNA mutation or genome profiling.
Functional characterization of the cell, for instance through ex-vivo analysis of response to anticancer drugs, can provide predictive information that are superior to genetic/molecular profiling, according to recent scientific literature.
At Cellply we are re-designing ex-vivo drug response analysis to support biology-driven therapy selection. Our goal is to set a new standard in precision oncology by developing a new class of instruments and technologies to unveil new clinical information deriving from live cell analysis.
Cellply develops the first diagnostic platform to predict the efficacy of the therapy
through the ex-vivo analysis of pharmacological response of patient cells and tissues
Drug response profiles are extracted and computed for each patient/drug through ex-vivo analysis of drug response.
Cell function and viability start changing a few hours after sampling. Cellply analysis, enabled by an analytical platform made available in the clinical setting, can start right after sampling and lasts just 24 hours. Being fast means being able to capture information on cell-drug interaction while cells are still mimicking in-vivo response.
In-between molecules and organisms, the biology of cells, tissues and organs constitutes information currently missing in the clinical decision-making. Cellply technology adds a new layer of information supporting better patient stratification, in combination with existing data.